En Es
Categories

Industry News

Mesa Laboratories to Acquire Molecular Diagnostics Tools Company Agena Bioscience

By Labmedica International staff writers
15 Sep 2021

IllustrationMesa Laboratories, Inc. (Lakewood, CO, USA) has entered into a definitive agreement to acquire Agena Bioscience, Inc. (San Diego, CA, USA).

Mesa is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring) to help its customers ensure product integrity, increase patient and worker safety, and improve the quality of life.

Agena is a leading molecular diagnostics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally. The company’s highly sensitive and cost-effective mass spectrometry-based platform, the MassARRAY System, is used globally in diverse research fields such as cancer profiling for solid tumors and liquid biopsies, inherited genetic disease testing, pharmacogenetics and clinical research.

“Agena brings an innovative approach to the challenges of clinical genomics. Their MassArray system is a proven platform which integrates the best of mass spectroscopy and multiplex PCR; providing a unique combination of sensitivity, cost effectiveness, fast turnaround time, ease of use, and flexibility,” said Gary Owens, President and Chief Executive Officer of Mesa. “These benefits strongly address the needs of clinicians to apply patient specific genomic information to make personalized treatment and monitoring decisions. We believe that The Mesa Way approach to continuous improvement will help the Agena team to continue to rapidly scale both commercially and operationally.”

“We are proud of our track record in bringing the power of genomics to the clinical setting in hereditary diseases, pharmacogenomics, oncology, infectious disease and sample integrity testing,” added Peter Dansky, Chief Executive Officer of Agena, who will join Mesa to lead the new Clinical Genomics Division. “Our robust technology platform along with deep customer partnership has been the foundation of our success. We built our company based on a strong team-oriented values system, and we see a great fit with the Mesa culture. We look forward to working with the Mesa team to expand the applications we deliver and innovate new technologies for clinical genomics.”

Related Links:
Mesa Laboratories, Inc.
Agena Bioscience, Inc.




E-mail Print
FaceBook Twitter Google+ Linked in

Agena Bioscience

Agena Bioscience is dedicated to advancing the impact of genomics in healthcare and precision medicine with a mission is to equip genomic and clinical testing laboratories with practical solutions that increase productivity and decrease time to results. Whether assessing sample quality, screening samples for actionable mutations, or enabling routine genetic testing for tens to thousands of samples, the company’s products and services help laboratories translate genomic discoveries into mainstream clinical practice.
More info

Additional news

25 Nov 2021
Global Point of Care Diagnostics Market to Top USD 35 Billion by 2027 Due to Rising Diabetic Cases
The global point of care diagnostics market is projected to grow at a CAGR of close to 6% from more than USD 23 billion in 2020 to over USD 35 billion by 2027, driven by an increase in the number of diabetic cases, technological developments in point of care devices and increased investments by the key players.
Read More
24 Nov 2021
Euromedlab Congress 2021 Postponed as Fourth COVID-19 Wave Hits Germany
The XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2021) to be held as an in-presence meeting between 28th of November and 2nd of December in Germany has been postponed as the country has been hit very hard by a fourth wave of COVID-19.
Read More
19 Nov 2021
44th World Hospital Congress (WHC) Ends on Upbeat Note as Hospital Leaders Look to Build Resilience
The 44th World Hospital Congress (WHC) organized by The International Hospital Federation (IHF; Geneva, Switzerland) on 8-11 November 2021 in Barcelona, Spain came to an upbeat close.
Read More
16 Nov 2021
Deborah Bowen (USA) Takes Up Position of IHF President for 2021-2023
Deborah Bowen has taken up the position of President of the International Hospital Federation (IHF; Geneva, Switzerland) following her election in 2019 and a two-year term as President Designate.
Read More
16 Nov 2021
IHF and Deloitte Collaborate to Launch Special Interest Group on Leadership for Sustainability
The International Hospital Federation (IHF; Geneva, Switzerland) will collaborate with Deloitte (London, UK) to launch a special interest group (SIG) centered around leadership for sustainability.
Read More
16 Nov 2021
International Hospital Federation (IHF) Announces Winners of IHF Awards 2021
The International Hospital Federation (IHF; Geneva, Switzerland) announced the winners of the IHF Awards 2021 as part of a special ceremony at the 44th World Hospital Congress (WHC) held in Barcelona, Spain.
Read More
13 Nov 2021
GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health
General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023.
Read More
11 Nov 2021
Blood Borne Testing Market to Witness Exponential Growth Due to Rising Incidence of Bacterial Infections
The global blood borne testing market is projected to record an exponential CAGR of over 7-8% during 2021-2031, driven by increasing bacterial infection and growing adoption of point of care devices, aided further by technological advancement in devices for blood borne pathogens. These are the latest findings of Fact.MR (Dublin, Ireland), a market research firm.
Read More
10 Nov 2021
AI in Radiology Market Driven by Growing Adoption of Machine Learning Tools in Broad Spectrum of Imaging Applications
The use of AI algorithms in medical image analysis field has made astounding progress. Particularly deep learning has made incessant inroads in radiology practice. The major consumer proposition for companies in the AI in radiology market stems from the exceptional capabilities of AI tools in recognizing complex patterns in the imaging data. These are the latest findings of Transparency Market Research (Albany NY, USA).
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions